Discussion on the genetic mechanisms and efficacy of growth hormone therapy in children with idiopathic short stature

MAMAT Mireguli

doi:10.7499/j.issn.1008-8830.2408040

PDF(563 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (12) : 1255-1260. DOI: 10.7499/j.issn.1008-8830.2408040

SERIES REVIEW—DIAGNOSIS AND TREATMENT OF GROWTH DISORDERS

Discussion on the genetic mechanisms and efficacy of growth hormone therapy in children with idiopathic short stature

MAMAT Mireguli

Author information +

History +

Abstract

Idiopathic short stature (ISS) is a term that encompasses a group of short stature disorders with unknown etiology. The genetic factors associated with ISS are complex, and the known genetic mechanisms include alterations in hormones, hormone receptors, or related pathways, defects in fundamental cellular processes (such as intracellular signaling pathways and transcriptional regulation), issues with extracellular matrix or paracrine signaling, as well as genetic variations in the genes encoding these proteins. Recombinant human growth hormone (rhGH) therapy is currently an effective clinical method for improving height in children with ISS. However, the efficacy of rhGH treatment on ISS varies among children with different genetic mechanisms. This paper analyzes and elucidates the genetic mechanisms of ISS and the effects of rhGH on ISS based on existing clinical research, aiming to enhance the understanding of ISS and provide references for improving the height of these children.

Key words

Idiopathic short stature / Genetic variation / Recombinant human growth hormone / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

MAMAT Mireguli. Discussion on the genetic mechanisms and efficacy of growth hormone therapy in children with idiopathic short stature[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(12): 1255-1260 https://doi.org/10.7499/j.issn.1008-8830.2408040

References

1 中华医学会儿科学分会内分泌遗传代谢学组, 中国医师协会青春期健康与医学专业委员会, 福棠儿童医学发展研究中心, 等. 儿童特发性矮身材诊断与治疗中国专家共识[J]. 中国实用儿科杂志, 2023, 38(11): 801-813. DOI: 10.19538/j.ek2023110601.
2 Zhao Q, Zhang M, Li Y, et al. Molecular diagnosis is an important indicator for response to growth hormone therapy in children with short stature[J]. Clin Chim Acta, 2024, 554: 117779. PMID: 38220134. DOI: 10.1016/j.cca.2024.117779.
3 卫海燕. 从循证医学证据看生长激素促生长治疗的收益及风险[J]. 中国实用儿科杂志, 2021, 36(8): 607-612. DOI: 10.19538/j.ek2021080610.
4 Ross JL, Lee PA, Gut R, et al. Attaining genetic height potential: analysis of height outcomes from the ANSWER program in children treated with growth hormone over 5 years[J]. Growth Horm IGF Res, 2015, 25(6): 286-293. PMID: 26363846. DOI: 10.1016/j.ghir.2015.08.006.
5 Wu D, Chen RM, Chen SK, et al. Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty[J]. BMC Pediatr, 2020, 20(1): 138. PMID: 32222149. PMCID: PMC7102429. DOI: 10.1186/s12887-020-02034-8.
6 冯鑫, 王春林. 特发性矮小症多组学生物标志物的研究进展[J]. 国际儿科学杂志, 2023, 50(11): 746-749. DOI: 10.3760/cma.j.issn.1673-4408.2023.11.007.
7 Shao X, Le Stunff C, Cheung W, et al. Differentially methylated CpGs in response to growth hormone administration in children with idiopathic short stature[J]. Clin Epigenetics, 2022, 14(1): 65. PMID: 35585611. PMCID: PMC9118695. DOI: 10.1186/s13148-022-01281-z.
8 奚立, 罗飞宏. 从内分泌激素角度审视身材矮小的评估[J]. 中国实用儿科杂志, 2021, 36(8): 581-585. DOI: 10.19538/j.ek2021080605.
9 Andrade NLM, Cellin LP, Rezende RC, et al. Idiopathic short stature: what to expect from genomic investigations[J]. Endocrines, 2023, 4(1): 1-17. DOI: 10.3390/endocrines4010001.
10 苏杨. 重组人生长激素治疗特发性矮身材儿童的临床疗效及安全性分析[D]. 长春: 吉林大学, 2022.
11 Singh A, Pajni K, Panigrahi I, et al. Components of IGF-axis in growth disorders: a systematic review and patent landscape report[J]. Endocrine, 2022, 76(3): 509-525. PMID: 35523998. DOI: 10.1007/s12020-022-03063-2.
12 应艳琴, 梁雁. 儿童特发性矮身材的遗传学机制进展[J]. 中国实用儿科杂志, 2023, 38(11): 818-822. DOI: 10.19538/j.ek2023110603.
13 Vasques GA, Andrade NLM, Jorge AAL. Genetic causes of isolated short stature[J]. Arch Endocrinol Metab, 2019, 63(1): 70-78. PMID: 30864634. PMCID: PMC10118839. DOI: 10.20945/2359-3997000000105.
14 Kumar A, Jain V, Chowdhury MR, et al. Pathogenic/likely pathogenic variants in the SHOX, GHR and IGFALS genes among Indian children with idiopathic short stature[J]. J Pediatr Endocrinol Metab, 2020, 33(1): 79-88. PMID: 31834863. DOI: 10.1515/jpem-2019-0234.
15 Fujimoto M, Andrew M, Dauber A. Disorders caused by genetic defects associated with GH-dependent genes: PAPPA2 defects[J]. Mol Cell Endocrinol, 2020, 518: 110967. PMID: 32739295. PMCID: PMC7609568. DOI: 10.1016/j.mce.2020.110967.
16 朱高慧, 朱岷. 生长板相关的儿童原发性生长障碍[J]. 中国实用儿科杂志, 2023, 38(11): 823-828. DOI: 10.19538/j.ek2023110604.
17 Vasques GA, Funari MFA, Ferreira FM, et al. IHH gene mutations causing short stature with nonspecific skeletal abnormalities and response to growth hormone therapy[J]. J Clin Endocrinol Metab, 2018, 103(2): 604-614. PMID: 29155992. DOI: 10.1210/jc.2017-02026.
18 梁雁, 罗小平. 儿童矮身材遗传学诊断与研究的挑战和机遇[J]. 中华儿科杂志, 2020, 58(6): 443-446. PMID: 32521954. DOI: 10.3760/cma.j.cn112140-20200421-00415.
19 Stavber L, Gaia MJ, Hovnik T, et al. Heterozygous NPR2 variants in idiopathic short stature[J]. Genes (Basel), 2022, 13(6): 1065. PMID: 35741827. PMCID: PMC9222219. DOI: 10.3390/genes13061065.
20 Li X, Yao R, Chang G, et al. Clinical profiles and genetic spectra of 814 Chinese children with short stature[J]. J Clin Endocrinol Metab, 2022, 107(4): 972-985. PMID: 34850017. PMCID: PMC8947318. DOI: 10.1210/clinem/dgab863.
21 Inzaghi E, Reiter E, Cianfarani S. The challenge of defining and investigating the causes of idiopathic short stature and finding an effective therapy[J]. Horm Res Paediatr, 2019, 92(2): 71-83. PMID: 31578025. DOI: 10.1159/000502901.
22 Hu X, Gui B, Su J, et al. Novel pathogenic ACAN variants in non-syndromic short stature patients[J]. Clin Chim Acta, 2017, 469: 126-129. PMID: 28396070. DOI: 10.1016/j.cca.2017.04.004.
23 ??klar Z, Kocaay P, ?amtosun E, et al. The effect of recombinant growth hormone treatment in children with idiopathic short stature and low insulin-like growth factor-1 levels[J]. J Clin Res Pediatr Endocrinol, 2015, 7(4): 301-306. PMID: 26777041. PMCID: PMC4805225. DOI: 10.4274/jcrpe.2111.
24 Monzani A, Babu D, Mellone S, et al. Co-occurrence of genomic imbalances on Xp22.1 in the SHOX region and 15q25.2 in a girl with short stature, precocious puberty, urogenital malformations and bone anomalies[J]. BMC Med Genomics, 2019, 12(1): 5. PMID: 30626445. PMCID: PMC6327496. DOI: 10.1186/s12920-018-0445-8.
25 Sandoval GT, Jaimes GC, Barrios MC, et al. SHOX gene and conserved noncoding element deletions/duplications in Colombian patients with idiopathic short stature[J]. Mol Genet Genomic Med, 2014, 2(2): 95-102. PMID: 24689071. PMCID: PMC3960050. DOI: 10.1002/mgg3.39.
26 Bakker B, Frane J, Anhalt H, et al. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children[J]. J Clin Endocrinol Metab, 2008, 93(2): 352-357. PMID: 18000092. DOI: 10.1210/jc.2007-1581.
27 S?vendahl L, Polak M, Backeljauw P, et al. Treatment of children with GH in the United States and Europe: long-term follow-up from NordiNet? IOS and ANSWER program[J]. J Clin Endocrinol Metab, 2019, 104(10): 4730-4742. PMID: 31305924. PMCID: PMC6812718. DOI: 10.1210/jc.2019-00775.
28 Wu B, Lin H, Gao J, et al. Effects of high-dose recombinant human growth hormone treatment on IGF-1 and IGFBP-3 levels in idiopathic dwarfism patients[J]. Pak J Med Sci, 2022, 38(4Part/II): 1038-1042. PMID: 35634620. PMCID: PMC9121936. DOI: 10.12669/pjms.38.4.5502.
29 Yuan K, Chen J, Chen Q, et al. NPR2 gene variants in familial short stature: a single-center study[J]. J Pediatr Endocrinol Metab, 2022, 35(2): 185-190. PMID: 34565054. DOI: 10.1515/jpem-2021-0332.
30 Plachy L, Dusatkova P, Maratova K, et al. NPR2 variants are frequent among children with familiar short stature and respond well to growth hormone therapy[J]. J Clin Endocrinol Metab, 2020, 105(3): dgaa037. PMID: 31990356. DOI: 10.1210/clinem/dgaa037.
31 Ke X, Liang H, Miao H, et al. Clinical characteristics of Short-Stature patients with an NPR2 mutation and the therapeutic response to rhGH[J]. J Clin Endocrinol Metab, 2021, 106(2): 431-441. PMID: 33205215. DOI: 10.1210/clinem/dgaa842.
32 Lin L, Li M, Luo J, et al. A high proportion of novel ACAN mutations and their prevalence in a large cohort of Chinese short stature children[J]. J Clin Endocrinol Metab, 2021, 106(7): e2711-e2719. PMID: 33606014. PMCID: PMC8208663. DOI: 10.1210/clinem/dgab088.
33 Sun J, Jiang L, Liu G, et al. Evaluation of growth hormone therapy in seven Chinese children with familial short stature caused by novel ACAN variants[J]. Front Pediatr, 2022, 10: 819074. PMID: 35330881. PMCID: PMC8940281. DOI: 10.3389/fped.2022.819074.
34 Savage MO, Storr HL. GH resistance is a component of idiopathic short stature: implications for rhGH therapy[J]. Front Endocrinol (Lausanne), 2021, 12: 781044. PMID: 34956092. PMCID: PMC8702638. DOI: 10.3389/fendo.2021.781044.